Ocugen completes enrollment for phase 3 retinitis pigmentosa trial
Tweet Send to a Friend
Ocugen Inc. (NASDAQ: OCGN) announced completion of enrollment for its Phase 3 liMeliGhT clinical trial testing OCU400, a gene therapy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
